Breast cancer drug developer Olema charts $100M IPO

The San Francisco company started a clinical trial in August for its experimental metastatic breast cancer drug.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.